WT1 in Ovarian Carcinoma: A Workhorse Stain for Histotype and Prognosis

What the Test Measures

WT1 is the protein product of the Wilms tumour 1 gene, a transcription factor with roles in mesodermal and mesothelial development. In the diagnostic ovarian setting we don't care much about its developmental biology — we care that its nuclear expression tracks tightly with serous lineage. That correlation is the whole point of the stain.

Here's the essential contrast. Where WT1 nuclear expression is retained in serous carcinomas — both high-grade (HGSC) and low-grade (LGSC) — it's conspicuously absent in clear cell, endometrioid, and mucinous carcinomas [1,2]. One marker, two worlds. That binary behaviour is what makes WT1 so serviceable in the histotyping panel, because ovarian carcinoma is not one disease but a family of biologically distinct tumours, each with its own natural history and therapeutic logic.

How It's Tested

The assay is immunohistochemistry (IHC) performed on formalin-fixed, paraffin-embedded (FFPE) tissue — the ordinary block that comes out of nearly every resection or biopsy. No special handling beyond standard fixation is required, though the usual preanalytic caveats apply: poorly fixed, over-decalcified, or ischaemic tissue can degrade nuclear antigenicity and give you a falsely faint result.

Scoring is deliberately simple. WT1 is read as nuclear expression present versus absent, yielding two result states: WT1+ or WT1−. It's a nuclear stain, and that matters — cytoplasmic blush should not be mistaken for a positive result, a trap for the inexperienced eye. Appropriate internal controls (fallopian tube epithelium, mesothelium) help confirm the run worked before you commit to calling a tumour negative.

What Each Result State Means

A WT1+ result supports serous differentiation. In the ovary that means HGSC or LGSC, the two ends of the serous spectrum [1,2]. This is where the stain earns its keep: it anchors a morphologically ambiguous tumour to the serous family.

A WT1− result pushes the interpretation the other way — toward clear cell, endometrioid, or mucinous carcinoma [1,2]. Negativity is not a diagnosis by itself; it's a signpost that narrows the differential and tells you which additional markers to reach for.

Worth emphasizing here is that WT1 rarely works alone. In practice the stain is most useful embedded in a panel — alongside markers of the endometrioid and clear cell phenotypes — where its result either corroborates or contradicts the morphology. A convincingly WT1+ tumour with papillary architecture and marked nuclear atypia reads comfortably as HGSC. A WT1− tumour with hobnail cells and clear cytoplasm steers you toward clear cell carcinoma. The evidence base for these associations is the diagnostic IHC standard reflected in the current classification [1].

What It Determines for Treatment Eligibility

WT1 does not, by itself, make anyone eligible for a drug. What it does is establish histotype, and histotype is what drives the therapeutic pathway. That indirection is important to state plainly for a mixed readership.

By supporting a serous diagnosis, a WT1+ result places a tumour within the group whose management is built around the serous carcinoma paradigm — informing eligibility for the drug classes deployed against HGSC and LGSC. By contrast, a WT1− result that resolves into clear cell, endometrioid, or mucinous carcinoma routes the patient toward the entirely different therapeutic logic those histotypes carry, since they respond and behave unlike their serous counterparts. The stain is one node in that decision tree; the histotype it helps establish is the node that connects to therapy. None of this is treatment advice — it's the diagnostic scaffolding on which treatment decisions are later built.

Caveats and What's Evolving

WT1 is durable, but it isn't infallible, and knowing where it stumbles is half the skill.

The single most treacherous scenario is uterine versus ovarian serous carcinoma. WT1 was originally proposed partly to help distinguish these, and while ovarian serous tumours are typically positive, uterine serous carcinomas can show variable expression [2]. So a WT1+ pelvic serous carcinoma does not automatically localize to the ovary — clinical, radiologic, and gross findings still carry weight. Treat the marker as one contributor to site assignment, not the arbiter.

Then there's the weak or focal stain. When nuclear positivity is patchy or faint, the honest move is to hedge: repeat the stain, check that the controls performed, and refuse to over-read a borderline result into a confident histotype. A weakly positive tumour in the wrong morphologic company deserves scepticism, not certainty. Focal WT1 expression has been described outside the classic serous setting, and a small subset of endometrioid tumours may show unexpected reactivity — which is precisely why the marker is interpreted against the whole panel rather than in isolation.

Finally, remember what WT1 is not. It is a lineage marker, not a grade or a stage. It tells you the tumour is likely serous; it does not distinguish high-grade from low-grade serous carcinoma, which rests on nuclear atypia, mitotic rate, and other stains. Reading prognostic meaning into WT1 status alone overreaches what the stain can support.

That WT1 has survived successive revisions of ovarian carcinoma classification tells you something. Markers that are merely convenient tend to fade as schemes are refined; those that reflect genuine biological lineage tend to persist. WT1's staying power is a quiet vote of confidence in the serous-versus-non-serous divide it maps — a divide that has proven more fundamental to how these tumours arise and behave than the older architectural labels it partly replaced. For the practising pathologist, that's the reassurance that when the stain and the morphology agree, they're agreeing about something real.

References

1. WHO Classification of Tumours Editorial Board. Female Genital Tumours, 5th ed. IARC, Lyon; 2020. ISBN 978-92-832-4504-9.
2. Al-Hussaini M, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. 2004. PMID:14764054.